摘要
嘌呤能系统由嘌呤和嘧啶递质、调节核苷酸和核苷相互转化的酶、控制它们的受体的膜转运体组成。无细胞浓度,以及许多受体亚型,负责他们的细胞反应。这个系统的组成部分在所有的组织和器官中都有广泛的定位。R参与了几种生理条件已被清楚地证明。此外,在像tiss这样的病理条件下,细胞外嘌呤和嘧啶的浓度增加了几倍。UE损伤,缺血和炎症,这表明这一信号系统可能有助于疾病的结果,并可能,它的初步解决。这个系统的复杂性由于不同的受体亚型所扮演的角色往往相反,实际上参与某一特定病理过程的介质和受体的明确识别受到了严重的损害。n然而,这些知识对于可能利用这些分子实体作为开发新的药理方法的目标是非常重要的。在这篇综述中,我们的目标是高效率。了解目前已知的嘌呤能系统在各种疼痛状态和炎症过程中的作用。虽然有些混淆可能会从相互矛盾的结果中产生,但文献数据清楚地表明,靶向特定的嘌呤能受体可能是治疗各种疼痛和炎症状态的一种创新方法,而新的嘌呤类药物现在非常接近r。每个市场都有这些迹象。
关键词: P1受体、P2X受体、P2Y受体、腺苷、ATP、UTP、核糖核苷酶、膜转运蛋白。
Current Medicinal Chemistry
Title:Tackling Chronic Pain and Inflammation through the Purinergic System
Volume: 25 Issue: 32
关键词: P1受体、P2X受体、P2Y受体、腺苷、ATP、UTP、核糖核苷酶、膜转运蛋白。
摘要: The purinergic system is composed of purine and pyrimidine transmitters, the enzymes that modulate the interconversion of nucleotides and nucleosides, the membrane transporters that control their extracellular concentrations, and the many receptor subtypes that are responsible for their cellular responses. The components of this system are ubiquitously localized in all tissues and organs, and their involvement in several physiological conditions has been clearly demonstrated. Moreover, extracellular purine and pyrimidine concentrations rise several folds under pathological conditions like tissue damage, ischemia, and inflammation, which suggest that this signaling system might contribute both to disease outcome and, possibly, to its tentative resolution. The complexity of this system has greatly impaired the clear identification of the mediators and receptors that are actually involved in a given pathology, also due to the often opposite roles played by the various receptor subtypes. Nevertheless, this knowledge is fundamental for the possible exploitation of these molecular entities as targets for the development of new pharmacological approaches. In this review, we aim at highlighting what is currently known on the role of the purinergic system in various pain conditions and during inflammatory processes. Although some confusion may arise from conflicting results, literature data clearly show that targeting specific purinergic receptors may represent an innovative approach to various pain and inflammatory conditions, and that new purine-based drugs are now very close to reach the market with these indications.
Export Options
About this article
Cite this article as:
Tackling Chronic Pain and Inflammation through the Purinergic System, Current Medicinal Chemistry 2018; 25 (32) . https://dx.doi.org/10.2174/0929867324666170710110630
DOI https://dx.doi.org/10.2174/0929867324666170710110630 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
Current Drug Targets Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews Role of Inflammatory Cells and Toll-Like Receptors in Atherosclerosis
Current Vascular Pharmacology Neuroinflammation in Demyelinating Diseases: Oxidative Stress as a Modulator of Glial Cross-Talk
Current Pharmaceutical Design Evaluation of the Effects of a New Drug on Brain Leukocyte Infiltration in an Experimental Model of Autoimmune Encephalomyelitis
Letters in Drug Design & Discovery A Central Role for ATP Signalling in Glial Interactions in the CNS
Current Drug Targets Scope and Applications of Nanomedicines for the Management of Multiple Sclerosis
Current Drug Metabolism M2000, Foundation of a New Generation Among NSAIDs
Letters in Drug Design & Discovery Recent Advances in Neuro-Endocrine-Immune Interactions in the Pathophysiology of Rheumatoid Arthritis
Current Rheumatology Reviews Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews Etiological and Biological Aspects of Cigarette Smoking in Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Multiple Sclerosis - A Coordinated Immune Attack Across the Blood Brain Barrier
Current Neurovascular Research NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Therapeutic Manipulation of the Immune System: Enhancement of Innate and Adaptive Mucosal Immunity
Current Pharmaceutical Design Differential Kinetics and Inhibition of Purified Recombinant Tyrosine Kinase 2 (TYK-2) and Its Catalytic Domain JH-1
Protein & Peptide Letters Can Environmentally Relevant Levels of Aluminium Promote the Onset and Progression of Neurodegenerative Diseases?
Current Inorganic Chemistry (Discontinued) Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple Sclerosis
Current Pharmaceutical Biotechnology